4/4
04:49 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/4
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4
09:54 am
smmt
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months [Yahoo! Finance]
Medium
Report
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months [Yahoo! Finance]
3/26
08:01 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
3/23
08:50 am
smmt
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
Medium
Report
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
3/21
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/17
04:38 pm
smmt
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer [Yahoo! Finance]
3/17
04:24 pm
smmt
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
Low
Report
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
3/14
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/12
07:38 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
3/5
02:04 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/28
11:11 am
smmt
Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts [Yahoo! Finance]
Medium
Report
Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts [Yahoo! Finance]
2/28
07:37 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $42.00 price target on the stock.
High
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $42.00 price target on the stock.
2/25
11:05 pm
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/25
05:36 pm
smmt
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer [Yahoo! Finance]
Low
Report
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer [Yahoo! Finance]
2/25
05:36 pm
smmt
Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? [Yahoo! Finance]
Low
Report
Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? [Yahoo! Finance]
2/25
08:00 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
2/25
04:27 am
smmt
Q4 2024 Summit Therapeutics Inc Earnings Call [Yahoo! Finance]
Medium
Report
Q4 2024 Summit Therapeutics Inc Earnings Call [Yahoo! Finance]
2/25
02:19 am
smmt
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... [Yahoo! Finance]
Medium
Report
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... [Yahoo! Finance]
2/24
08:13 pm
smmt
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Medium
Report
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
2/24
03:34 pm
smmt
https://seekingalpha.com/article/4761382-summit-therapeutics-mid-2025-nsclc-data-could-further-entrench-ivonescimab-program [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4761382-summit-therapeutics-mid-2025-nsclc-data-could-further-entrench-ivonescimab-program [Seeking Alpha]
2/24
11:21 am
smmt
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss [Yahoo! Finance]
Medium
Report
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss [Yahoo! Finance]
2/24
08:48 am
smmt
Summit Therapeutics Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
High
Report
Summit Therapeutics Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]